

rythm of the heart starts from SA node---atrial tissues -----AV node ----ventricle bundle
----right and left bundle branches-----to while muscular to produce normal cardiac output

Antiarrhythmic Drugs

Munir Gharaibeh MD, PhD, MHPE
School of Medicine,
The University of Jordan
October 2019

Done by : Maryam Ali

Cardiac Arrhythmias

Definition.

any disturbance in the electrical pathway

Etiology:

Any disturbance in heart rhythm will affect the heart function

Hereditary genetic causes of arrhythmias or non-arrhythmias

Acquired

Types: two types of abnormalities:

- **Abnormalities of Impulse Formation:**

electrical system in the SA , AV nodes or in ventricle and atrium

Rate disturbances. could be high or slow lead to tachycardia or bradycardia

Triggered automaticity.

abnormality in any part in the heart to produce action potential

- **Abnormalities of Impulse Conduction:**

heart blocks-----delay of conduction

Blocks.

Reentry. recirculation of cardiac action potential in the same place

Cardiac Causes of Arrhythmias

■ **Ischemic heart disease.** affect the muscle
affect the neuropathway

■ **Inflammation.** viral disease----causes ----endocarditis


■ **Trauma e.g. heart surgery.** having heart failure or maybe death
after surgery

■ **Congestive heart failure.** causing dialation , hypertrophy of the
heart then cause heart failure

■ **Hypotension.** will affect baroreceptor---- to increase the heart rate--- then having
tachycardia

Non Cardiac causes Arrhythmias


- **Electrolyte imbalance.**
- **Acid-Base imbalance.**
- **Hypoxia.**
- **Drugs:**
 - **Digitalis** most important cause-----> used in heart failure
 - **Anesthetics**
 - **Tricyclic** antidepressant drug
 - **Diuretics**
 - **Bronchodilators: sympathomimetic.** useful in asthma
will stimulate the heart rate
- **Reflexes.**
 - such as GI reflexes , vasovagal reflexes-----> can cause bradycardia




Ion Permeability Changes

Potential Changes

Genes and Proteins



Na current -- starts at phase zero in a sudden way



genes control of the channels

Gene/protein

SCN5A/Nav 1.5

CACNA1/Cav 1.2

CACNA1G, 1/Cav 3.1, 3.2

KCND3/Kv 4.3

KCNA4/Kv 1.4

KCNA1/KvLQT 1

KCNH2/hERG

KCNA5/Kv 1.5

??

CFTR/CFTR

KCNJ1/Kir 2.1

HCN2, 4/HCN2, 4

SLC8A1/NCX 1

NKA1N1-4/Na, K-pump

ca current --- appears in phase 1,2,3




they consumed energy -- found all over the body
sodium goes out , potassium enters

Cardiac Na⁺ channels

Resting

Activated

Inactivated




Recovery


main channel
Na⁺

-terminated of the electricity
-due to the different direction of
impulses

Purkinje Fiber



The main source
for phase 4 depolarization
in Purkinje fibers
is I_f




I_{KACH} I_f I_{K1} I_{Na} I_{Ca} $I_{Kr} & I_{Ks}$

all phases can be
found 1,2,3,4


Currents that regulate
pacemaking

SA Node

Multiple currents
regulate SA Node
automaticity,
including I_f & I_{Ca}





3- has important application
in many drugs
-main channel Ca²⁺





I_{KACH} I_f I_K I_{Ca} $I_{Kr} & I_{Ks}$

only phase 0,3,4
NO--> 1,2

Sinoatrial node




Contractile myocardium




SA node automaticity

ability to produce (generate) impulses without any help---> by itself can generate impulses



Normal Circuitry

Purkinje twig



there are different
direction of the impulses
that will terminate the electricity
without re-circulation

A. Normal conduction

Source: Katzung BG, Masters SB, Trevor AJ: *Basic & Clinical Pharmacology*,
11th Edition: <http://www.accessmedicine.com>


October 19

Munir Gharalbeh MD, PhD, MHPE

11

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Re-entry Rhythm







B. Unidirectional block

Source: Katzung BG, Masters SB, Trevor AJ: *Basic & Clinical Pharmacology*, 11th Edition: <http://www.accessmedicine.com>

October 19

Munir Gharaibeh MD, PhD, MHPE

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.



Pre-requisites for Reentry (Circus Movement)

- **Anatomic or physiologic obstacle.**
- **Unidirectional block.**
- **Conduction time around the circuit must be longer than the effective refractory period.**


TABLE 14-1 Molecular and genetic basis of some cardiac arrhythmias.

has different types

Type	Chromosome Involved	Defective Gene	Ion Channel or Proteins Affected	Result
LQT-1 long QT	11	<i>KCNQ1</i>	I_{Ks}	lose function LF
LQT-2	7	<i>KCNH2 (HERG)</i>	I_{Kr}	lose function LF
LQT-3	3	<i>SCN5A</i>	I_{Na}	gain function GF
LQT-4	4	Ankyrin-B ¹		LF
LQT-5	21	<i>KCNE1 (minK)</i>	I_{Ks}	LF
LQT-6	21	<i>KCNE2 (MiRP1)</i>	I_{Kr}	LF
LQT-7 ²	17	<i>KCNJ2</i>	I_{Kir}	LF
LQT-8 ³	12	<i>CACNA1c</i>	I_{Ca}	GF
SQT-1 short QT	7	<i>KCNH2</i>	I_{Kr}	GF
SQT-2	11	<i>KCNQ1</i>	I_{Ks}	GF
SQT-3	17	<i>KCNJ2</i>	I_{Kir}	GF
CPVT-1 Catecholaminergic polymorphic ventricular tachycardia	1	<i>hRyR2</i>	Ryanodine receptor	GF
CPVT-2	1	<i>CASQ2</i>	Calsequestrin	LF
Sick sinus syndrome	15 or 3	<i>HCN4 or SCN5A</i> ⁵		LF
Brugada syndrome	3	<i>SCN5A</i>	I_{Na}	LF
PCCD	3	<i>SCN5A</i>	I_{Na}	LF
Familial atrial fibrillation	11	<i>KCNQ1</i>	I_{Ks}	GF

ECG of some Arrhythmias

can diagnose different types of arrhythmias , and sometimes iit can't



A: SVT

supraventricular
tachycardia
- having high heart
rate

B: AFL

C: AFib

D: VT

E: VT-TdP

Torsade de Pointes Polymorphic Ventricular Tachycardia

long QT transient attack
LQT, syncope, and sudden death.

Causes:

- **Familial long QT interval**
- **Drug - Induced (drugs which prolong APD).**
- **Genetic mutations: 300 different mutations in at least 8 ion channel genes.**

action potential
duration

Mechanisms:


- **Increased inward current (GF), or**
- **Decreased outward current (LF) during the plateau.**

gain function

lose
function

Figure 14-8

abnormal ECG



Source: Katzung BG, Masters SB, Trevor AJ: *Basic & Clinical Pharmacology*, 12th edition: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Electrocardiogram from a patient with the long QT syndrome during two episodes of torsades de pointes. The polymorphic ventricular tachycardia is seen at the start of this tracing and spontaneously halts at the middle of the panel. A single normal sinus beat (NSB) with an extremely prolonged QT interval follows, succeeded immediately by another episode of ventricular tachycardia of the torsades type. The usual symptoms include dizziness or transient loss of consciousness. (Reproduced, with permission, from *Basic and Clinical Pharmacology*, 10th edition, McGraw-Hill, 2007.)

Torsade de Pointes

Risk Factors:

having high level of K⁺
with normal renal function then K⁺
will get out through urine

* BUT

having renal failure then there will be accumulation
of K⁺

- **Bradycardia.**
- **Hypokalemia.** Can cause various types of arrhythmias
- **Triggered upstrokes.**
- **Drugs which ↑ APD.**

Treatment:

- **K⁺** to avoid hypokalemia
- **↓ Triggered upstrokes (β Blockers or Mg⁺⁺)**
- **↓ APD (Pacemaker or isoproterenol).**

www.sads.org = sudden arrhythmia death syndrome foundation



SADS FOUNDATION

SUDDEN ARRHYTHMIA DEATH SYNDROMES

Supporting Families.
Saving Lives.

Donate

What is SADS?

[SADS Blog](#) [About Us](#) [Contact Us](#) [Library](#)

[Advocacy](#)

[Schools](#)

[Medical Professionals](#)

[Get Involved](#)

[Living with SADS](#)

[Research](#)



Take Steps to Stop SADS!

Munir Gharabeh MD, PhD, MHPE

October 19



Stay Connected!
Sign up for SADS eNews

Online Community

- SADS Online Support Community
- SADSConnect for Youth
- Share Your Story
- Stories: Living & Thriving with SADS
- Stories: Forever in our Hearts
- Enews Archives & Sign up

20

Other Congenital Arrhythmias

■ Short QT Syndrome:

- GF mutations in three potassium channel genes (KCNH2, KCNQ1, and KCNJ2).

■ Chatecholaminergic Polymorphic Ventricular Tachycardia (CPVT):

- Stress or emotion-induced syncope.
- Caused by mutations in sarcoplasmic proteins that control calcium.

Other Congenital Arrhythmias

■ Sick Sinus Syndrome:

- Mutations in HCN4 and SCN5A

■ Brugada Syndrome:

- Ventricular fibrillation, persistent ST elevation, and BBB(5 in 10,000).
- Linked to LF mutations in SCN5A

■ Familial Atrial Fibrillation:

- Linked to GF mutation in the potassium channel gene, KCNQ1.


Nonpharmacologic Therapy

- **Surgery.**
- **Radiofrequency Catheter Ablation (إستئصال).**
- **Cryoablation.** extreme cold to destroy tissue
- **Implantable Cardioverter- Defibrillator (ICD).**
- **Gene therapy!!!!.**

Principles of Mechanisms of Action of Antiarrhythmic Drugs

- Readily bind to activated channels or inactivated channels, but bind poorly to rested channels.
i.e.: *Use –Dependent or State-Dependent.*
- Channels in normal cells will rapidly lose the drug from the receptors during the resting portion of the cycle.
- This selectivity is lost with increasing doses, leading to drug-induced arrhythmias.
- Also, these drugs may become” *Proarrhythmic or Arrhythmogenic*” during fast heart rates, acidosis, hyperkalemia, or ischemia.

Possible Effects of Drugs on Action Potential






Table 17.1 The mechanism of action, the electrophysiological actions and clinical uses of selected antidysrhythmic drugs

	Example	Mechanism of action	Electrophysiological actions	Clinical use	
● Vaughan Williams classification	<u>Class Ia</u>	Disopyramide	Na ⁺ channel block	Reduced rate of depolarisation of action potential, increased ERP, decreased AV conduction	Ventricular fibrillation, especially associated with myocardial infarction
	<u>Class Ib</u>	Lidocaine			
	<u>Class II</u>	Propranolol, atenolol	<u>β-Adrenoceptor antagonism</u>	Slowed pacemaker activity, increased AV refractory period	Dysrhythmia prevention in myocardial infarction; paroxysmal atrial fibrillation due to sympathetic activity
	<u>Class III</u>	Amiodarone, sotalol	<u>K⁺ channel block</u>	Increased action potential duration and increased ERP	Atrial fibrillation; ventricular fibrillation
	<u>Class IV</u>	Verapamil	<u>Ca²⁺ channel block</u>	Decreased APD, slowed AV conduction	Supraventricular tachycardias; atrial fibrillation
● Not classified by system	Adenosine	K ⁺ channel activation	Slowed pacemaker activity, slowed AV conduction	Given i.v. for supraventricular tachycardias	
	Digoxin	K ⁺ channel activation (vagal action)	Slowed AV conduction (block)	Atrial fibrillation	
	Magnesium chloride	? Ca ²⁺ channel block		Ventricular fibrillation; digoxin toxicity	

Table 21.2 Summary of antidysrhythmic drugs (Vaughan Williams classification)

Class	Example(s)	Mechanism
Ia	Disopyramide	Sodium-channel block (intermediate dissociation)
Ib	Lidocaine	Sodium-channel block (fast dissociation)
Ic	Flecainide	Sodium-channel block (slow dissociation)
II	Propranolol	β -Adrenoceptor antagonism
III	Amiodarone, sotalol	Potassium-channel block
IV	Verapamil	Calcium-channel block




Fig. 21.9 Effects of antidysrhythmic drugs on the different phases (as defined in **Fig. 21.1**) of the cardiac action potential.

Drugs Affecting the Cardiac Action Potential





TABLE 14-3 Clinical pharmacologic properties of antiarrhythmic drugs.

Drug	Effect on SA Nodal Rate	Effect on AV Nodal Refractory Period		QRS Duration	QT Interval	Usefulness in Arrhythmias		Half-Life
		PR Interval				Supra-ventricular	Ventricular	
Adenosine	↓↑	↑↑↑	↑↑↑	0	0	++++	?	< 10 s
Amiodarone	↓↓ ¹	↑↑	Variable	↑	↑↑↑↑	+++	+++	(weeks)
Diltiazem	↑↓	↑↑	↑	0	0	+++	-	4-8 h
Disopyramide	↑↓ ^{1,2}	↑↓ ²	↑↓ ²	↑↑	↑↑	+	+++	7-8 h
Dofetilide	↓(?)	0	0	0	↑↑	++	None	7 h
Dronedarone					↑	+++	-	24 h
Esmolol	↓↓	↑↑	↑↑	0	0	+	+	10 min
Flecainide	None, ↓	↑	↑	↑↑↑	0	+ ³	++++	20 h
Ibutilide	↓(?)	0	0	0	↑↑	++	?	6 h
Lidocaine	None ¹	None	0	0	0	None ⁴	+++	1-2 h
Mexiletine	None ¹	None	0	0	0	None	+++	12 h
Procainamide	↓ ¹	↑↓ ²	↑↓ ²	↑↑	↑↑	+	+++	3-4 h
Propafenone	0, ↓	↑	↑	↑↑↑	0	+	+++	5-7 h
Propranolol	↓↓	↑↑	↑↑	0	0	+	+	5 h
Quinidine	↑↓ ^{1,2}	↑↓ ²	↑↓ ²	↑↑	↑↑	+	+++	6 h
Sotalol	↓↓	↑↑	↑↑	0	↑↑↑	+++	+++	7 h
Verapamil	↓↓	↑↑	↑↑	0	0	+++	-	7 h
Vernakalant		↑	↑			+++	-	2 h

Class I Antiarrhythmic Drug Effects

On the Ventricular Action Potential:



On the ECG:

that why antiarrhythmic drug could be proarrhythmic because it lead to have long QT

↑QRS & ↑QT


↓QT

↑↑QRS

Class 1A Drugs

old drug

Quinidine:



- Prototype, related to quinine.
- Cinchona tree → Antipyretic
→ Quinine = Antimalarial.
- Inhibits α and muscarinic receptors.
- Slows upstroke, conduction, and prolongs APD and QRS duration.

Quinidine

- **Use nowadays restricted to patients with normal hearts(no failure, no ischemia), but have atrial or ventricular arrhythmias.**

Quinidine


Side Effects: Toxic

- Nausea (18%), Diarrhea (33%).
- Headache, Dizziness, and tinnitus= **Cinchonism**
- Hypersensitivity, fever, rash, angioedema.
- Thrombocytopenia.
- Excessive prolongation of QT interval, slowed conduction and sudden death (TdP).
- Hypotension.
- ↑Serum Digoxin levels.
- ↑ Warfarin effects.
- **Sudden death.** common side effect in antiarrhythmic drug but much more common in Quindine

Class 1A Drugs

new agent

Procainamide:



- Oral, but has short $t_{1/2}$.
- ^{lupus erythematosus} L.E. (30% of patients Tx over 6 moths)
- ^{converted to} Acetylated → NAPA (Class III) action


Disopyramide

- More anticholinergic effects but less diarrhea than quinidine

Class 1B Drugs

Lidocaine: for ventricular arrhythmias

- High affinity to bind with activated and inactivated Na⁺ channels with rapid kinetics.
- Acts selectively in ischemic tissue to promote conduction & block reentry.
- More effective with ↑ K⁺.
- Not effective in atrial arrhythmias.



Class 1B Drugs

Lidocaine: IV another name xylocaine

Kinetics:

- Well absorbed, but ineffective orally, due to first pass effect, so given IV.
- Well distributed, including the brain.

Side Effects:

- Least cardiotoxic of the class, except for hypotension with high doses due to depression of the myocardium.
- main side effect at high doses CNS: paresthesia, tremor, nausea, slurred speech, and convulsions. reduce by sedative
- *Was routinely given to all MI patients to prevent ventricular arrhythmias.*

Class 1B Drugs

Tocainide:

- Oral analog of lidocaine.
- CNS, GI and blood dyscrasia.

Mexiletine:

- Oral analog of lidocaine.
- Neurologic side effects.

Phenytoin:

- Antiepileptic.
- For Digitalis- induced arrhythmias.
- For arrhythmias after congenital heart surgery.
- Also for, Congenital prolonged QT interval.

Class 1C Drugs

Flecainide:

- Potent blocker of Na⁺ and K⁺ channels.
- Negative inotropic effect.
- Proarrhythmic → ventricular.
- Effective in supra ventricular tachycardia with normal hearts.
- Side Effects: Ventricular arrhythmias, CNS, and sudden death.

Class 1C Drugs

Propafenone:

- Blocks Na⁺ channels but also has beta blocking and Ca⁺⁺ blocking activity.
- No effect on QT interval.
- Used for supraventricular arrhythmias.
- Side effects: metallic taste, constipation, and arrhythmias.

has CNS effect can cross BBB

Class II Drugs

Propranolol:

old drug - prototype-
can reduce the demand of O₂ to the heart
can reduce the electrical activity of the heart

- Besides **beta blocking**, membrane stabilization, and intrinsic sympathomimetic activities, has effective antiarrhythmic activity
- Very effective, well tolerated, and **documented to reduce mortality after acute myocardial infarction by reducing arrhythmias, besides reducing myocardial oxygen requirements.**

Class II Drugs

Esmolol:

2-3 times per day

- Short acting, used in intraoperative and acute arrhythmias
- β_1 selective
- No membrane stabilization effect.

Acebutolol:

- Short acting, used in intraoperative and acute arrhythmias.
- β_1 -selective.
- Has direct membrane stabilizing effects.


Class III Drugs

can be classified as class 1,2,3,4

Amiodarone:

prevent atrial and ventricular arrhythmias

prevent the entry of K⁺



prolongs

Blocks K⁺ channels
APD.

Class I actions.

Blocks α and β Receptors.

Ca⁺⁺ blocking actions._{class 4}

Effect is due to alteration of lipid membrane.

Reserved for life-threatening atrial and ventricular arrhythmias. _{treatment for chronic arrhythmias}

Slows heart rate and AV conduction.

Low incidence of TdP despite significant QT prolongation. _{can prevent the conversion of ventricular arrhythmia into ventricular fibrillation}

Peripheral vasodilator (only with IV).

subjected to drug interaction

Class III Drugs

it increases QT
NO Tdp

Amiodarone:

because it has long half life

- Given IV (Loading dose 10gm) and orally.
- Slow kinetics ($t_{1/2}$ 25-110 days), metabolized by CYP3A4 enzymes.



Toxicity: *mainly extracardiac and dose related.*

no effect on the heart

major side effects:

- Lung fibrosis (1%). this one can affect the heart
- CNS.
- Thyroid(hypo and hyper). in hypo- can be treated by given thyroxin
- GI and liver.
- Corneal deposits,
- Skin: photodermatitis and discoloration blue man syndrom , to treat this state --> by reducing the dose
- ↑ Digoxin & Anticoagulants.
- Interactions: affected by CYP3A4 activity.

Blue-man Syndrome



Class III Drugs

Bretylium Tosylate:

- Originally an **antihypertensive**, but tolerance develops.
- Releases NE, then ↓ Release / Reuptake
- Rarely used, except for prevention of ventricular fibrillation after failure of cardioversion and lidocaine.
- side effects: Hypotension, Parotid swelling.

Class III Drugs

Sotalol:

- Beta blocker but has Class III actions.
- For atrial and ventricular arrhythmias.
- Causes bradycardia, HF, and Prolongation of QT. Heart failure
can inance TdP

■ Ibutilide.

■ Dofetilide.

calcium can cause vasodilation

Class IV Drugs (Ca⁺⁺ Channel Blockers)

calcium is important in our bodies: stimulate some of hormones to be release neurotransmitters, and the movement of chromosomes during division

Verapamil

Diltiazem

Block activated and inactivated L-type Ca⁺⁺ channels.

- Effects more marked in tissues that fire frequently, less completely polarized at rest, and those dependant on Ca⁺⁺ (SA node and AV node).
- ***Paroxysmal Supraventricular Tachycardia.*** benign form
- Vasodilators and have negative inotropic effects.
- Can cause severe AV block in diseased hearts.
- Relatively safe: Constipation, gastric discomfort, vertigo, headache, nervousness, pruritis.
- **↑ Digoxin levels.** very important in treatment of HF

Table 21.1 Antidysrhythmic drugs unclassified in the Vaughan Williams system

Drug	Use
Atropine anticholinergic drug	Sinus bradycardia
Adrenaline (epinephrine)	Cardiac arrest intracardial injection
Isoprenaline beta agonist	Heart block
Digoxin	Rapid atrial fibrillation and heart failure
Adenosine	Supraventricular tachycardia
Calcium chloride	Ventricular tachycardia due to hyperkalaemia
Magnesium chloride	Ventricular fibrillation, digoxin toxicity

Unclassified Drugs

Digoxin:

- Old fashioned agent for heart failure and atrial arrhythmias.
- Direct Actions. on SA node
- Vagotonic Effects. stimulate vagus nerve indirectly
- ↑ AV refractoriness.

can prevent the absorption of calcium
in the GI

Unclassified Drugs

Magnesium:

- Works on Na^+/K^+ ATPase, Na^+ channels, certain K^+ channels and Ca^{++} channels.
- Effective IV in refractory digitalis- induced ventricular arrhythmias only in hypomagnesemic patients.
- Also, in TdP patients even if serum Mg^{++} is normal.

Potassium salts:

- For digitalis- induced arrhythmias with hypokalemia.
- Depress ectopic pacemakers and slow conduction.

Unclassified Drugs

Adenosine:

- Naturally occurring nucleoside.
- Stimulates purinergic(P1) receptors.
- Activates inward rectifier K⁺ current and inhibits Ca⁺⁺ current.
- Very short acting (t 1/2 10 seconds).
- ↓ Phase 4 depolarization in SA node.
- ↓ AV conduction.
- No effect on ventricles.

Unclassified Drugs

Adenosine:

- 90-95% effective in supraventricular tachycardia, replaced verapamil.
- Less effective in the presence of adenosine receptor blockers, e.g. theophylline and caffeine.
- Can cause transient flushing (20%), chest tightness, AV block, headache, hypotension, nausea, and paresthesia.